Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
3.370
+0.050 (1.51%)
At close: Mar 19, 2026, 4:00 PM EDT
3.350
-0.020 (-0.59%)
Pre-market: Mar 20, 2026, 8:50 AM EDT
Recursion Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts that cover Recursion Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $7.50, which forecasts a 122.55% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $11.
Price Target: $7.50 (+122.55%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Recursion Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 2 | 2 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Hold Maintains $7 → $6 | Hold | Maintains | $7 → $6 | +78.04% | Feb 26, 2026 |
| Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +137.39% | Feb 26, 2026 |
| JP Morgan | JP Morgan | Hold → Buy Upgrades $10 → $11 | Hold → Buy | Upgrades | $10 → $11 | +226.41% | Dec 17, 2025 |
| Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +137.39% | Sep 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +137.39% | Jul 8, 2025 |
Financial Forecast
Revenue This Year
83.73M
from 74.68M
Increased by 12.11%
Revenue Next Year
152.82M
from 83.73M
Increased by 82.52%
EPS This Year
-0.98
from -1.44
EPS Next Year
-0.87
from -0.98
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 110.3M | 336.0M | |
| Avg | 83.7M | 152.8M | |
| Low | 70.1M | 73.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 47.6% | 301.3% | |
| Avg | 12.1% | 82.5% | |
| Low | -6.2% | -12.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.66 | -0.64 | |
| Avg | -0.98 | -0.87 | |
| Low | -1.13 | -0.94 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.